302 research outputs found
Enriching Remote Control Applications with Fog Computing
Fog computing has emerged in the recent years as a paradigm tailored to serve geo-distributed applications requiring low latency. Remote Control (RC) applications allow a mobile device to control another device from remote. To enrich Quality of Experience (QoE) of RC applications, in this paper we investigate the use of fog computing as a viable platform to offload computation of tasks that would be expensive if performed locally on a mobile device. The proposed approach, supported with next 5G communication systems, will enable a Tactile Internet experience. In this paper we study and compare offload policies to accommodate tasks in the fog platform and analyze the requirements to minimize outages
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
The present analysis, carried out in the context of a randomized phase III trial, confirms superior outcomes for breast cancer patients for whom chemotherapy induces pathological complete response (pCR) after adjusting for other important prognostic factors. In contrast, when tumours do not achieve pCR, patients have a higher risk of relapse. This effect is observed in all intrinsic subtypes and justifies the current interest in post-neoadjuvant trial
22 – uPA-PAI-1 et paramètres clinicopathologiques classiques dans la prise en charge individualisée des cancers primaires du sein
94. Pronostic et prise en charge du cancer du sein chez la femme âgée de plus de 70 ans : étude d’une cohorte de 1 723 patientes traitées en Languedoc-Roussillon (base OPTALR)
95. Cancer du sein de la femme âgée : pronostic, prise en charge et survie des tumeurs infracentimétriques
Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C omparison Study. Methods: Patients who completed 36 months of treatment (Part 1) of the European IFNb-1a Dose-C omparison Study were given the option to continue double-blind treatment with IFNb-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NA b) formation. Results: O f 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNb-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48 and 43, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: C ompared with 60-mcg IM IFNb-1a once weekly, a dose of 30 mcg IM IFNb-1a once weekly maintains the same clinical efficacy over four years
- …